Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | recruiting | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05230758 | Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour(Met Med Can) | recruiting | Phase 3 | 140 | Donald MabbottOTHER | 2 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT05237934 | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05363319 | An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe(CEMI-LUNG) | recruiting | — | 500 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 24, 2026 | clinicaltrials |
| NCT05412225 | A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05520255 | 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028 | recruiting | Phase 3 | 2,800 | University of AlbertaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05640999 | Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | recruiting | Phase 2 | 393 | Canadian Cancer Trials GroupNETWORK | 9 | Sep 24, 2026 | clinicaltrials |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | recruiting | Phase 3 | 670 | Iovance Biotherapeutics, Inc.INDUSTRY | 16 | Sep 24, 2026 | clinicaltrials |
| NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | recruiting | Phase 2 | 100 | PfizerINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT05752136 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | recruiting | Phase 3 | 108 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | recruiting | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05842044 | NSAID Use After Robotic Partial Nephrectomy(No-PAIN) | recruiting | Phase 2 | 110 | University of MiamiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | recruiting | Phase 3 | 408 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05898789 | Virtual Rehabilitation for Cancer Survivors | recruiting | N/A | 388 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | recruiting | Phase 3 | 735 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 24, 2026 | clinicaltrials |
| NCT05949125 | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)(RevSTAR-123) | recruiting | Phase 1 | 37 | AvenCell Europe GmbHINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06037941 | Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma | recruiting | N/A | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06057935 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06123338 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | recruiting | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | recruiting | Phase 3 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | recruiting | Phase 3 | 478 | National Cancer Institute (NCI)NIH | 5 | Sep 24, 2026 | clinicaltrials |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06424327 | A Registry for People With Lung Cancer | recruiting | — | 600 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06522568 | Testing a Mammography Decision Intervention in a Rural Setting | recruiting | N/A | 39 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06529575 | Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children(PACH) | recruiting | — | 650 | University of PennsylvaniaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06563479 | A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer | recruiting | Phase 3 | 291 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06605404 | Pan-tumor MRD Study | recruiting | — | 1,350 | Paradigm HealthINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | recruiting | Phase 4 | 60 | AstraZenecaINDUSTRY | 6 | Sep 24, 2026 | clinicaltrials |
| NCT06693336 | An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | recruiting | Phase 2 | 42 | ToLymph Inc.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06828822 | CongenItal Naevus Cohort for Longitudinal Evaluation(CIRCLE) | recruiting | N/A | 819 | Nantes University HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06871410 | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06890598 | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer(SUNRAY-02) | recruiting | Phase 3 | 700 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT06911008 | MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers | recruiting | Phase 1 | 42 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06995872 | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07068074 | Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma | recruiting | Phase 3 | 428 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07182240 | Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas | recruiting | N/A | 60 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07223463 | A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer | recruiting | N/A | 160 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07225491 | Spine Oncology Registry | recruiting | — | 3,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07247123 | Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program | recruiting | N/A | 280 | National University Hospital, SingaporeOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | recruiting | Phase 1 | 24 | Providence Health & ServicesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07438626 | Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 24, 2026source: clinicaltrials